Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) Director Purchases 6,266 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) Director Robert F. Williamson III acquired 6,266 shares of Perspective Therapeutics stock in a transaction on Monday, November 25th. The stock was purchased at an average cost of $3.64 per share, for a total transaction of $22,808.24. Following the purchase, the director now owns 430,058 shares in the company, valued at approximately $1,565,411.12. The trade was a 1.48 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Perspective Therapeutics Price Performance

CATX stock opened at $4.12 on Friday. Perspective Therapeutics, Inc. has a one year low of $2.28 and a one year high of $19.05. The firm has a 50-day simple moving average of $10.78 and a two-hundred day simple moving average of $12.32.

Perspective Therapeutics (NYSE:CATX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Equities research analysts expect that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CATX. Vanguard Group Inc. grew its position in Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth $15,511,000. FMR LLC lifted its stake in shares of Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares during the period. State Street Corp increased its position in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after acquiring an additional 1,192,812 shares during the period. Finally, Nicholson Wealth Management Group LLC purchased a new position in Perspective Therapeutics in the 3rd quarter worth $21,390,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $5.00 in a research note on Monday. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target for the company. Royal Bank of Canada reduced their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating on the stock in a research report on Monday. UBS Group started coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 target price for the company. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.14.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.